Locations:
Search
First report of major endpoint reduction in patients with biopsy-proven NASH
TMAO pathway impacts infarct size and functional impairment in preclinical stroke models
Cleveland Clinic-led study supports investigation of similar immunomodulatory therapies
Review of our recent experience shows it’s still a safe option
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Machine learning may improve risk prediction and guide therapy
High-dose omega-3 fatty acid conferred no outcomes benefit over corn oil in high-risk patients
Phase 3 study may lead to first FDA approval for the indication
Analysis used echocardiographic data to assess structural valve deterioration
Results achieved despite increased complexity and venous occlusive disease
Our early experience shows lower-than-reported incidence, hints at role for neutrophilia
Advertisement
Advertisement